The average performance of two-sample testing approaches with smaller population. by Ioannis Bargiotas (3390458)

“…Decreasing the population leads to lower chance of distinguishing the two groups. …”

Individual based stochastic simulation as two type Moran process. by Benjamin Werner (194068)

“…During the next time step three cases are possible: (i) the number of resistant cells increases by one with probability , (ii) stays the same with probability (iii) or decreases by one with probability , (see equation (2a) and (2b)).…”

DataSheet_2_Nasal and cutaneous mucormycosis in two patients with lymphoma after chemotherapy and target therapy: Early detection by metagenomic next-generation sequencing.xls by Qing Zhang (1802)

“…Metagenomic next-generation sequencing (mNGS) is an innovative and sensitive technique used to identify pathogenic strains. Here we used mNGS to timely diagnose an infection with Lichtheimia ramosa and Mucor irregularis in two patients with hematologic malignancies; the infections manifested as nasal and cutaneous infections and developed after chemotherapy and small molecule targeted therapy. …”

Data_Sheet_2_Endoglin and squamous cell carcinomas.DOCX by Sarah K. Hakuno (16381851)

image5_Chemoresistance in Breast Cancer Patients Associated With Changes in P2X7 and A2A Purinergic Receptors in CD8+ T Lymphocytes.jpeg by Victor Manuel Ruiz-Rodríguez (9704699)

“…In this sense, as the chemotherapeutic treatment stimulates immune system response, we evaluated the expression and function of P2X7 and A2A receptors in CD8⁺ T cells before and four months after BRCA patients received neoadjuvant chemotherapy. …”

image5_Chemoresistance in Breast Cancer Patients Associated With Changes in P2X7 and A2A Purinergic Receptors in CD8+ T Lymphocytes.jpeg by Victor Manuel Ruiz-Rodríguez (9704699)

“…In this sense, as the chemotherapeutic treatment stimulates immune system response, we evaluated the expression and function of P2X7 and A2A receptors in CD8⁺ T cells before and four months after BRCA patients received neoadjuvant chemotherapy. …”

image4_Chemoresistance in Breast Cancer Patients Associated With Changes in P2X7 and A2A Purinergic Receptors in CD8+ T Lymphocytes.jpeg by Victor Manuel Ruiz-Rodríguez (9704699)

“…In this sense, as the chemotherapeutic treatment stimulates immune system response, we evaluated the expression and function of P2X7 and A2A receptors in CD8⁺ T cells before and four months after BRCA patients received neoadjuvant chemotherapy. …”

image1_Chemoresistance in Breast Cancer Patients Associated With Changes in P2X7 and A2A Purinergic Receptors in CD8+ T Lymphocytes.jpeg by Victor Manuel Ruiz-Rodríguez (9704699)

“…In this sense, as the chemotherapeutic treatment stimulates immune system response, we evaluated the expression and function of P2X7 and A2A receptors in CD8⁺ T cells before and four months after BRCA patients received neoadjuvant chemotherapy. …”

Table_2_The temperature-dependent expression of type II secretion system controls extracellular product secretion and virulence in mesophilic Aeromonas salmonida SRW-OG1.docx by Xin Yi (180644)

“…In this study, by constructing the mutants of tatA, tatB, and tatC, we investigated the mechanisms underlying temperature-dependent virulence regulation in mesophilic A. salmonida SRW-OG1. …”

image3_Chemoresistance in Breast Cancer Patients Associated With Changes in P2X7 and A2A Purinergic Receptors in CD8+ T Lymphocytes.jpeg by Victor Manuel Ruiz-Rodríguez (9704699)

“…In this sense, as the chemotherapeutic treatment stimulates immune system response, we evaluated the expression and function of P2X7 and A2A receptors in CD8⁺ T cells before and four months after BRCA patients received neoadjuvant chemotherapy. …”

image4_Chemoresistance in Breast Cancer Patients Associated With Changes in P2X7 and A2A Purinergic Receptors in CD8+ T Lymphocytes.jpeg by Victor Manuel Ruiz-Rodríguez (9704699)

“…In this sense, as the chemotherapeutic treatment stimulates immune system response, we evaluated the expression and function of P2X7 and A2A receptors in CD8⁺ T cells before and four months after BRCA patients received neoadjuvant chemotherapy. …”

datasheet1_Chemoresistance in Breast Cancer Patients Associated With Changes in P2X7 and A2A Purinergic Receptors in CD8+ T Lymphocytes.docx by Victor Manuel Ruiz-Rodríguez (9704699)

“…In this sense, as the chemotherapeutic treatment stimulates immune system response, we evaluated the expression and function of P2X7 and A2A receptors in CD8⁺ T cells before and four months after BRCA patients received neoadjuvant chemotherapy. …”

image3_Chemoresistance in Breast Cancer Patients Associated With Changes in P2X7 and A2A Purinergic Receptors in CD8+ T Lymphocytes.jpeg by Victor Manuel Ruiz-Rodríguez (9704699)

“…In this sense, as the chemotherapeutic treatment stimulates immune system response, we evaluated the expression and function of P2X7 and A2A receptors in CD8⁺ T cells before and four months after BRCA patients received neoadjuvant chemotherapy. …”

datasheet1_Chemoresistance in Breast Cancer Patients Associated With Changes in P2X7 and A2A Purinergic Receptors in CD8+ T Lymphocytes.docx by Victor Manuel Ruiz-Rodríguez (9704699)

“…In this sense, as the chemotherapeutic treatment stimulates immune system response, we evaluated the expression and function of P2X7 and A2A receptors in CD8⁺ T cells before and four months after BRCA patients received neoadjuvant chemotherapy. …”

image1_Chemoresistance in Breast Cancer Patients Associated With Changes in P2X7 and A2A Purinergic Receptors in CD8+ T Lymphocytes.jpeg by Victor Manuel Ruiz-Rodríguez (9704699)

“…In this sense, as the chemotherapeutic treatment stimulates immune system response, we evaluated the expression and function of P2X7 and A2A receptors in CD8⁺ T cells before and four months after BRCA patients received neoadjuvant chemotherapy. …”

Image4_Loganin Inhibits Angiotensin II–Induced Cardiac Hypertrophy Through the JAK2/STAT3 and NF-κB Signaling Pathways.JPEG by Jia-jia Xu (10966923)

“…Hence, the aim of the present study was to investigate the effect of loganin on Ang II–induced cardiac hypertrophy. In the present study, we reported for the first time that loganin inhibits Ang II–provoked cardiac hypertrophy and cardiac damages in H9C2 cells and in mice. …”

Image1_Loganin Inhibits Angiotensin II–Induced Cardiac Hypertrophy Through the JAK2/STAT3 and NF-κB Signaling Pathways.JPEG by Jia-jia Xu (10966923)

“…Hence, the aim of the present study was to investigate the effect of loganin on Ang II–induced cardiac hypertrophy. In the present study, we reported for the first time that loganin inhibits Ang II–provoked cardiac hypertrophy and cardiac damages in H9C2 cells and in mice. …”

Image3_Loganin Inhibits Angiotensin II–Induced Cardiac Hypertrophy Through the JAK2/STAT3 and NF-κB Signaling Pathways.JPEG by Jia-jia Xu (10966923)

“…Hence, the aim of the present study was to investigate the effect of loganin on Ang II–induced cardiac hypertrophy. In the present study, we reported for the first time that loganin inhibits Ang II–provoked cardiac hypertrophy and cardiac damages in H9C2 cells and in mice. …”

Table1_Loganin Inhibits Angiotensin II–Induced Cardiac Hypertrophy Through the JAK2/STAT3 and NF-κB Signaling Pathways.DOCX by Jia-jia Xu (10966923)

“…Hence, the aim of the present study was to investigate the effect of loganin on Ang II–induced cardiac hypertrophy. In the present study, we reported for the first time that loganin inhibits Ang II–provoked cardiac hypertrophy and cardiac damages in H9C2 cells and in mice. …”

Table2_Ectopic expression of SARS-CoV-2 S and ORF-9B proteins alters metabolic profiles and impairs contractile function in cardiomyocytes.xlsx by Peng Zhang (2071)

“…<p>Coronavirus disease 2019 (COVID-19) is associated with adverse impacts in the cardiovascular system, but the mechanisms driving this response remain unclear. In this study, we conducted “pseudoviral infection” of SARS-CoV-2 subunits to evaluate their toxic effects in cardiomyocytes (CMs), that were derived from human induced pluripotent stem cells (hiPSCs). …”